Current Report Filing (8-k)
December 08 2021 - 9:05AM
Edgar (US Regulatory)
0001504167
false
0001504167
2021-12-08
2021-12-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 8, 2021
TIMBER
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-37411
|
|
59-3843182
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
110 Allen Road, Suite 401
Basking Ridge,
NJ 07920
(Address of principal
executive offices)
Registrant’s
telephone number, including area code: (908)636-7160
N/A
(Former name or
former address, if changed since last report.)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title of
each class
|
|
Trading
Symbol(s)
|
|
Name of
each exchange on which registered
|
Common Stock, $0.001 Par Value
|
|
TMBR
|
|
The NYSE American, LLC
|
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
On
December 8, 2021, Timber Pharmaceuticals, Inc. (the “Company”) posted presentation materials (the “Investor Presentation”)
on the Investor Relations section of its website, which is located at https://www.timberpharma.com/events-and-presentation. A copy of
the Investor Presentation is attached as Exhibit 99.1 hereto.
The information in this Current Report on Form
8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission,
and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Timber Pharmaceuticals,
Inc.
|
|
|
Date: December
8, 2021
|
By:
|
/s/
John Koconis
|
|
Name:
|
John Koconis
|
|
Title:
|
Chief Executive Officer
|
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Sep 2023 to Sep 2024